Fremanezumab for Preventing Chronic Migraine

"The clinical trial is still looking for patients, according to the most recent information available on clinicaltrials.gov. This page was originally published on 7/30/2020 and was last updated on 8/23/2022."

"Currently, there are 35 hospitals or research centres taking part in this clinical trial. For example, Teva Investigational Site 14370 in Loma Linda, Teva Investigational Site 14360 in Covington, and Teva Investigational Site 14273 in Austin."

"Given that this is a Phase 3 trial with supporting data for efficacy and safety, our team has estimated the safety of Fremanezumab to be a 3."

"As of now, there are 4 ongoing studies for Fremanezumab that span 44 cities and 9 countries. The first study was done in 2020 by Teva Branded Pharmaceutical Products R&D, Inc. That initial Phase 3 trial had 288 participants and completed drug approval stages. In the two years since then, a total of 18292 studies have been conducted."

"The age range for this trial are individuals who have not yet reached their 18th birthday, but are older than 6 years old."

"This study is open to 418 participants, all of whom must be minors that have been diagnosed with migraines for over 6 months. Furthermore, these potential patients must also answer yes to the following questions: Have you experienced 8 migraines in the past month?, Have you experienced 15 headaches in the past month?, Are you applying as a caregiver on behalf of your child?"

"Yes, the clinical trial is recruiting participants at 35 sites across the United States. The trial was first posted on July 30th 2020 and was last updated on August 23rd 2022. A total of 418 patients are needed for the study."

"There are 4 active clinical trials studying Fremanezumab, 3 of which have advanced to Phase 3. Although the majority of these trials are based in Dresden, Illinois, there are a total of 241 sites running these studies across the world."